[1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127(12): 2893-2917.10.1002/ijc.25516]Search in Google Scholar
[2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65(1): 5-29.10.3322/caac.21254]Search in Google Scholar
[3. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer. 2008; 8(4): 268-278.10.1038/nrc2351]Search in Google Scholar
[4. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. The New England journal of medicine. 1991; 324(17): 1156-1161.10.1056/NEJM199104253241702]Search in Google Scholar
[5. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. The New England journal of medicine. 1987; 317(15): 909-916.10.1056/NEJM198710083171501]Search in Google Scholar
[6. Oberaigner W, Horninger W, Klocker H, Schonitzer D, Stuhlinger W, Bartsch G. Reduction of prostate cancer mortality in Tyrol, Austria, after introduction of prostate-specific antigen testing. Am J Epidemiol. 2006; 164(4): 376-384.10.1093/aje/kwj213]Search in Google Scholar
[7. Potosky AL, Feuer EJ, Levin DL. Impact of screening on incidence and mortality of prostate cancer in the United States. Epidemiol Rev. 2001; 23(1): 181-186.10.1093/oxfordjournals.epirev.a000787]Search in Google Scholar
[8. Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012; 61(6): 1079-1092.10.1016/j.eururo.2012.02.054]Search in Google Scholar
[9. Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol. 1995; 154(2 Pt 1): 407-413.10.1016/S0022-5347(01)67064-2]Search in Google Scholar
[10. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate- specific antigen level < or = 4.0 ng per milliliter. The New England journal of medicine. 2004; 350(22): 2239-2246.10.1056/NEJMoa03191815163773]Search in Google Scholar
[11. Thompson IM, Ankerst DP, Chi C, et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA. 2005; 294(1): 66-70.10.1001/jama.294.1.66]Search in Google Scholar
[12. Draisma G, Etzioni R, Tsodikov A, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst. 2009; 101(6): 374-383.10.1093/jnci/djp001]Search in Google Scholar
[13. Mohler J, Bahnson RR, Boston B, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw. 2010; 8(2): 162-200.10.6004/jnccn.2010.0012]Search in Google Scholar
[14. Lapointe J, Li C, Higgins JP, et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. 2004; 101(3): 811-816.10.1073/pnas.0304146101]Search in Google Scholar
[15. Sakr WA, Tefilli MV, Grignon DJ, et al. Gleason score 7 prostate cancer: a heterogeneous entity? Correlation with pathologic parameters and disease-free survival. Urology. 2000; 56(5): 730-734.10.1016/S0090-4295(00)00791-3]Search in Google Scholar
[16. Hori S, Blanchet JS, McLoughlin J. From prostatespecific antigen (PSA) to precursor PSA (proPSA) isoforms: a review of the emerging role of proPSAs in the detection and management of early prostate cancer. BJU Int. 2013; 112(6): 717-728.10.1111/j.1464-410X.2012.11329.x22759214]Search in Google Scholar
[17. Vlaeminck-Guillem V, Ruffion A, Andre J, Devonec M, Paparel P. Urinary prostate cancer 3 test: toward the age of reason? Urology. 2010; 75(2): 447-453.10.1016/j.urology.2009.03.04619586654]Search in Google Scholar
[18. Sartori DA, Chan DW. Biomarkers in prostate cancer: what's new? Curr Opin Oncol. 2014; 26(3): 259-264.10.1097/CCO.0000000000000065411068124626128]Search in Google Scholar
[19. Wolters T, van der Kwast TH, Vissers CJ, et al. False-negative prostate needle biopsies: frequency, histopathologic features, and follow-up. Am J Surg Pathol. 2010; 34(1): 35-43.10.1097/PAS.0b013e3181c3ece919935058]Search in Google Scholar
[20. Goo YA, Goodlett DR. Advances in proteomic prostate cancer biomarker discovery. J Proteomics. 2010; 73(10): 1839-1850.10.1016/j.jprot.2010.04.00220398807]Search in Google Scholar
[21. Pin E, Fredolini C, Petricoin EF, 3rd. The role of proteomics in prostate cancer research: biomarker discovery and validation. Clin Biochem. 2013; 46(6): 524-538.10.1016/j.clinbiochem.2012.12.012]Search in Google Scholar
[22. Fredolini C, Liotta LA, Petricoin EF. Application of proteomic technologies for prostate cancer detection, prognosis, and tailored therapy. Crit Rev Clin Lab Sci. 2010; 47(3): 125-138.10.3109/10408363.2010.503558]Search in Google Scholar
[23. Garbis SD, Townsend PA. Proteomics of human prostate cancer biospecimens: the global, systemswide perspective for protein markers with potential clinical utility. Expert Rev Proteomics. 2013; 10(4): 337-354.10.1586/14789450.2013.827408]Search in Google Scholar
[24. Larkin SE, Zeidan B, Taylor MG, et al. Proteomics in prostate cancer biomarker discovery. Expert Rev Proteomics. 2010; 7(1): 93-102.10.1586/epr.09.89]Search in Google Scholar
[25. Flatley B, Malone P, Cramer R. MALDI mass spectrometry in prostate cancer biomarker discovery. Biochim Biophys Acta. 2014; 1844(5): 940-949.10.1016/j.bbapap.2013.06.015]Search in Google Scholar
[26. Wright ME, Han DK, Aebersold R. Mass spectrometry- based expression profiling of clinical prostate cancer. Mol Cell Proteomics. 2005; 4(4): 545-554.10.1074/mcp.R500008-MCP200]Search in Google Scholar
[27. O'Farrell PH. High resolution two-dimensional electrophoresis of proteins. J Biol Chem. 1975; 250(10): 4007-4021.10.1016/S0021-9258(19)41496-8]Search in Google Scholar
[28. Unlu M, Morgan ME, Minden JS. Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis. 1997; 18(11): 2071-2077.10.1002/elps.1150181133]Search in Google Scholar
[29. Lilley KS, Friedman DB. All about DIGE: quantification technology for differential-display 2D-gel proteomics. Expert Rev Proteomics. 2004; 1(4): 401-409.10.1586/14789450.1.4.401]Search in Google Scholar
[30. Tonge R, Shaw J, Middleton B, et al. Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology. Proteomics. 2001; 1(3): 377-396.10.1002/1615-9861(200103)1:3<377::AID-PROT377>3.0.CO;2-6]Search in Google Scholar
[31. Rabilloud T, Lelong C. Two-dimensional gel electrophoresis in proteomics: a tutorial. J Proteomics. 2011; 74(10): 1829-1841.10.1016/j.jprot.2011.05.040]Search in Google Scholar
[32. Oliveira BM, Coorssen JR, Martins-de-Souza D. 2DE: the phoenix of proteomics. J Proteomics. 2014; 104: 140-150.10.1016/j.jprot.2014.03.035]Search in Google Scholar
[33. Link AJ, Eng J, Schieltz DM, et al. Direct analysis of protein complexes using mass spectrometry. Nat Biotechnol. 1999; 17(7): 676-682.10.1038/10890]Search in Google Scholar
[34. Patel VJ, Thalassinos K, Slade SE, et al. A comparison of labeling and label-free mass spectrometrybased proteomics approaches. J Proteome Res. 2009; 8(7): 3752-3759.10.1021/pr900080y]Search in Google Scholar
[35. Stahl DC, Swiderek KM, Davis MT, Lee TD. Datacontrolled automation of liquid chromatography/tandem mass spectrometry analysis of peptide mixtures. J Am Soc Mass Spectrom. 1996; 7(6): 532-540.10.1016/1044-0305(96)00057-8]Search in Google Scholar
[36. Silva JC, Gorenstein MV, Li GZ, Vissers JP, Geromanos SJ. Absolute quantification of proteins by LCMSE: a virtue of parallel MS acquisition. Mol Cell Proteomics. 2006; 5(1): 144-156.10.1074/mcp.M500230-MCP20016219938]Search in Google Scholar
[37. Liu Y, Chen J, Sethi A, et al. Glycoproteomic analysis of prostate cancer tissues by SWATH mass spectrometry discovers N-acylethanolamine acid amidase and protein tyrosine kinase 7 as signatures for tumor aggressiveness. Mol Cell Proteomics. 2014; 13(7): 1753-1768.10.1074/mcp.M114.038273408311324741114]Search in Google Scholar
[38. Liu Y, Huttenhain R, Collins B, Aebersold R. Mass spectrometric protein maps for biomarker discovery and clinical research. Expert Rev Mol Diagn. 2013; 13(8): 811-825.10.1586/14737159.2013.845089383381224138574]Search in Google Scholar
[39. Collins BC, Gillet LC, Rosenberger G, et al. Quantifying protein interaction dynamics by SWATH mass spectrometry: application to the 14-3-3 system. Nat Methods. 2013; 10(12): 1246-1253.10.1038/nmeth.270324162925]Search in Google Scholar
[40. Liu Y, Huttenhain R, Surinova S, et al. Quantitative measurements of N-linked glycoproteins in human plasma by SWATH-MS. Proteomics. 2013; 13(8): 1247-1256.10.1002/pmic.20120041723322582]Search in Google Scholar
[41. Kim Y, Ignatchenko V, Yao CQ, et al. Identification of differentially expressed proteins in direct expressed prostatic secretions of men with organ-confined versus extracapsular prostate cancer. Mol Cell Proteomics. 2012; 11(12): 1870-1884.10.1074/mcp.M112.017889351811322986220]Search in Google Scholar
[42. Principe S, Kim Y, Fontana S, et al. Identification of prostate-enriched proteins by in-depth proteomic analyses of expressed prostatic secretions in urine. J Proteome Res. 2012; 11(4): 2386-2396.10.1021/pr2011236364207422339264]Search in Google Scholar
[43. Wolters DA, Washburn MP, Yates JR, 3rd. An automated multidimensional protein identification technology for shotgun proteomics. Anal Chem. 2001; 73(23): 5683-5690.10.1021/ac010617e11774908]Search in Google Scholar
[44. Domon B, Aebersold R. Mass spectrometry and protein analysis. Science. 2006; 312(5771): 212-217.10.1126/science.112461916614208]Search in Google Scholar
[45. Pusch W, Kostrzewa M. Application of MALDITOF mass spectrometry in screening and diagnostic research. Curr Pharm Des. 2005; 11(20): 2577-2591.10.2174/138161205454693216101460]Search in Google Scholar
[46. Baggerly KA, Morris JS, Coombes KR. Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics. 2004; 20(5): 777-785.10.1093/bioinformatics/btg48414751995]Search in Google Scholar
[47. Wright GL, Jr. SELDI proteinchip MS: a platform for biomarker discovery and cancer diagnosis. Expert Rev Mol Diagn. 2002; 2(6): 549-563.10.1586/14737159.2.6.54912465452]Search in Google Scholar
[48. McLerran D, Grizzle WE, Feng Z, et al. SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin Chem. 2008; 54(1): 53-60.10.1373/clinchem.2007.091496433251518024530]Search in Google Scholar
[49. Kaiser T, Wittke S, Just I, et al. Capillary electrophoresis coupled to mass spectrometer for automated and robust polypeptide determination in body fluids for clinical use. Electrophoresis. 2004; 25(13): 2044-2055.10.1002/elps.20030578815237405]Search in Google Scholar
[50. Kolch W, Neususs C, Pelzing M, Mischak H. Capillary electrophoresis-mass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery. Mass Spectrom Rev. 2005; 24(6): 959-977.10.1002/mas.2005115747373]Search in Google Scholar
[51. Bhowmick NA, Moses HL. Tumor-stroma interactions. Curr Opin Genet Dev. 2005; 15(1): 97-101.10.1016/j.gde.2004.12.003]Search in Google Scholar
[52. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006; 6(5): 392-401.10.1038/nrc1877]Search in Google Scholar
[53. Paweletz CP, Liotta LA, Petricoin EF, 3rd. New technologies for biomarker analysis of prostate cancer progression: Laser capture microdissection and tissue proteomics. Urology. 2001; 57(4 Suppl 1): 160-163.10.1016/S0090-4295(00)00964-X]Search in Google Scholar
[54. Meehan KL, Holland JW, Dawkins HJ. Proteomic analysis of normal and malignant prostate tissue to identify novel proteins lost in cancer. Prostate. 2002; 50(1): 54-63.10.1002/pros.1003211757036]Search in Google Scholar
[55. Lin JF, Xu J, Tian HY, et al. Identification of candidate prostate cancer biomarkers in prostate needle biopsy specimens using proteomic analysis. Int J Cancer. 2007; 121(12): 2596-2605.10.1002/ijc.2301617722004]Search in Google Scholar
[56. Ummanni R, Junker H, Zimmermann U, et al. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer. Cancer Lett. 2008; 266(2): 171-185.10.1016/j.canlet.2008.02.04718384941]Search in Google Scholar
[57. Ummanni R, Mundt F, Pospisil H, et al. Identification of clinically relevant protein targets in prostate cancer with 2D-DIGE coupled mass spectrometry and systems biology network platform. PloS one. 2011; 6(2): e16833.10.1371/journal.pone.0016833303793721347291]Search in Google Scholar
[58. Han ZD, Zhang YQ, He HC, et al. Identification of novel serological tumor markers for human prostate cancer using integrative transcriptome and proteome analysis. Med Oncol. 2012; 29(4): 2877-2888.10.1007/s12032-011-0149-922215415]Search in Google Scholar
[59. Alaiya AA, Al-Mohanna M, Aslam M, et al. Proteomics- based signature for human benign prostate hyperplasia and prostate adenocarcinoma. Int J Oncol. 2011; 38(4): 1047-1057.10.3892/ijo.2011.93721305254]Search in Google Scholar
[60. Zheng Y, Xu Y, Ye B, et al. Prostate carcinoma tissue proteomics for biomarker discovery. Cancer. 2003; 98(12): 2576-2582.10.1002/cncr.1184914669276]Search in Google Scholar
[61. Cheung PK, Woolcock B, Adomat H, et al. Protein profiling of microdissected prostate tissue links growth differentiation factor 15 to prostate carcinogenesis. Cancer Res. 2004; 64(17): 5929-5933.10.1158/0008-5472.CAN-04-121615342369]Search in Google Scholar
[62 . Liu AY, Zhang H, Sorensen CM, Diamond DL. Analysis of prostate cancer by proteomics using tissue specimens. J Urol. 2005; 173(1): 73-78.10.1097/01.ju.0000146543.33543.a315592032]Search in Google Scholar
[63. Garbis SD, Tyritzis SI, Roumeliotis T, et al. Search for potential markers for prostate cancer diagnosis, prognosis and treatment in clinical tissue specimens using amine-specific isobaric tagging (iTRAQ) with two-dimensional liquid chromatography and tandem mass spectrometry. J Proteome Res. 2008; 7(8): 3146-3158.10.1021/pr800060r18553995]Search in Google Scholar
[64. Sun C, Song C, Ma Z, et al. Periostin identified as a potential biomarker of prostate cancer by iTRAQproteomics analysis of prostate biopsy. Proteome Sci. 2011; 9: 22.10.1186/1477-5956-9-22310023721504578]Search in Google Scholar
[65. Lexander H, Palmberg C, Hellman U, et al. Correlation of protein expression, Gleason score and DNA ploidy in prostate cancer. Proteomics. 2006; 6(15): 4370-4380.10.1002/pmic.20060014816888723]Search in Google Scholar
[66. Skvortsov S, Schafer G, Stasyk T, et al. Proteomics profiling of microdissected low- and high-grade prostate tumors identifies Lamin A as a discriminatory biomarker. J Proteome Res. 2011; 10(1): 259-268.10.1021/pr100921j20977276]Search in Google Scholar
[67. Khamis ZI, Iczkowski KA, Sahab ZJ, Sang QX. Protein profiling of isolated leukocytes, myofibroblasts, epithelial, Basal, and endothelial cells from normal, hyperplastic, cancerous, and inflammatory human prostate tissues. J Cancer. 2010; 1: 70-79.10.7150/jca.1.70293806820842227]Search in Google Scholar
[68. Pang J, Liu WP, Liu XP, et al. Profiling protein markers associated with lymph node metastasis in prostate cancer by DIGE-based proteomics analysis. J Proteome Res. 2010; 9(1): 216-226.10.1021/pr900953s19894759]Search in Google Scholar
[69. Glen A, Gan CS, Hamdy FC, et al. iTRAQ-facilitated proteomic analysis of human prostate cancer cells identifies proteins associated with progression. J Proteome Res. 2008; 7(3): 897-907.10.1021/pr070378x18232632]Search in Google Scholar
[70. Petricoin EF, 3rd, Ornstein DK, Paweletz CP, et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst. 2002; 94(20): 1576-1578.10.1093/jnci/94.20.157612381711]Search in Google Scholar
[71. Ornstein DK, Rayford W, Fusaro VA, et al. Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml. J Urol. 2004; 172(4 Pt 1): 1302-1305.10.1097/01.ju.0000139572.88463.3915371828]Search in Google Scholar
[72. Qu Y, Adam BL, Yasui Y, et al. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem. 2002; 48(10): 1835-1843.10.1093/clinchem/48.10.1835]Search in Google Scholar
[73. Adam BL, Qu Y, Davis JW, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res. 2002; 62(13): 3609-3614.]Search in Google Scholar
[74. Malik G, Ward MD, Gupta SK, et al. Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer. Clin Cancer Res. 2005; 11(3): 1073-1085.10.1158/1078-0432.1073.11.3]Search in Google Scholar
[75. Pan YZ, Xiao XY, Zhao D, et al. Application of surface- enhanced laser desorption/ionization time-offlight- based serum proteomic array technique for the early diagnosis of prostate cancer. Asian J Androl. 2006; 8(1): 45-51.10.1111/j.1745-7262.2006.00103.x16372118]Search in Google Scholar
[76. Kyselova Z, Mechref Y, Al Bataineh MM, et al. Alterations in the serum glycome due to metastatic prostate cancer. J Proteome Res. 2007; 6(5): 1822-1832.10.1021/pr060664t368517017432893]Search in Google Scholar
[77. Qin S, Ferdinand AS, Richie JP, O'Leary MP, Mok SC, Liu BC. Chromatofocusing fractionation and two-dimensional difference gel electrophoresis for low abundance serum proteins. Proteomics. 2005; 5(12): 3183-3192.10.1002/pmic.20040113716035113]Search in Google Scholar
[78. Jayapalan JJ, Ng KL, Razack AH, Hashim OH. Identification of potential complementary serum biomarkers to differentiate prostate cancer from benign prostatic hyperplasia using gel- and lectin-based proteomics analyses. Electrophoresis. 2012; 33(12): 1855-1862.10.1002/elps.20110060822740474]Search in Google Scholar
[79. Bergamini S, Bellei E, Reggiani Bonetti L, et al. Inflammation: an important parameter in the search of prostate cancer biomarkers. Proteome Sci. 2014; 12: 32.10.1186/1477-5956-12-32406177524944525]Search in Google Scholar
[80. Byrne JC, Downes MR, O'Donoghue N, et al. 2DDIGE as a strategy to identify serum markers for the progression of prostate cancer. J Proteome Res. 2009; 8(2): 942-957.10.1021/pr800570s19093873]Search in Google Scholar
[81. Fan Y, Murphy TB, Byrne JC, Brennan L, Fitzpatrick JM, Watson RW. Applying random forests to identify biomarker panels in serum 2D-DIGE data for the detection and staging of prostate cancer. J Proteome Res. 2011; 10(3): 1361-1373.10.1021/pr101106921166384]Search in Google Scholar
[82. Qingyi Z, Lin Y, Junhong W, et al. Unfavorable prognostic value of human PEDF decreased in highgrade prostatic intraepithelial neoplasia: a differential proteomics approach. Cancer Invest. 2009; 27(7): 794-801.10.1080/0735790080217561719637042]Search in Google Scholar
[83. Le L, Chi K, Tyldesley S, et al. Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions. Clin Chem. 2005; 51(4): 695-707.10.1373/clinchem.2004.04108715695329]Search in Google Scholar
[84. Al-Ruwaili JA, Larkin SE, Zeidan BA, et al. Discovery of serum protein biomarkers for prostate cancer progression by proteomic analysis. Cancer Genomics Proteomics. 2010; 7(2): 93-103.]Search in Google Scholar
[85. Rosenzweig CN, Zhang Z, Sun X, et al. Predicting prostate cancer biochemical recurrence using a panel of serum proteomic biomarkers. J Urol. 2009; 181(3): 1407-1414.10.1016/j.juro.2008.10.142413015019157448]Search in Google Scholar
[86. Lam YW, Mobley JA, Evans JE, Carmody JF, Ho SM. Mass profiling-directed isolation and identification of a stage-specific serologic protein biomarker of advanced prostate cancer. Proteomics. 2005; 5(11): 2927-2938.10.1002/pmic.20040116515952230]Search in Google Scholar
[87. Rehman I, Evans CA, Glen A, et al. iTRAQ identification of candidate serum biomarkers associated with metastatic progression of human prostate cancer. PloS one. 2012; 7(2): e30885.10.1371/journal.pone.0030885328025122355332]Search in Google Scholar
[88. Decramer S, Gonzalez de Peredo A, Breuil B, et al. Urine in clinical proteomics. Mol Cell Proteomics. 2008; 7(10): 1850-1862. 10.1074/mcp.R800001-MCP20018667409]Search in Google Scholar
[89. Rodriguez-Suarez E, Siwy J, Zurbig P, Mischak H. Urine as a source for clinical proteome analysis: from discovery to clinical application. Biochim Biophys Acta. 2014; 1844(5): 884-898.10.1016/j.bbapap.2013.06.01623831154]Search in Google Scholar
[90. Theodorescu D, Fliser D, Wittke S, et al. Pilot study of capillary electrophoresis coupled to mass spectrometry as a tool to define potential prostate cancer biomarkers in urine. Electrophoresis. 2005; 26(14): 2797-2808.10.1002/elps.20040020815981297]Search in Google Scholar
[91. Theodorescu D, Schiffer E, Bauer HW, et al. Discovery and validation of urinary biomarkers for prostate cancer. Proteomics Clin Appl. 2008; 2(4): 556-570.10.1002/prca.200780082274412619759844]Search in Google Scholar
[92. Schiffer E, Bick C, Grizelj B, Pietzker S, Schofer W. Urinary proteome analysis for prostate cancer diagnosis: cost-effective application in routine clinical practice in Germany. Int J Urol. 2012; 19(2): 118-125.10.1111/j.1442-2042.2011.02901.x22103570]Search in Google Scholar
[93. M'Koma AE, Blum DL, Norris JL, et al. Detection of pre-neoplastic and neoplastic prostate disease by MALDI profiling of urine. Biochem Biophys Res Commun. 2007; 353(3): 829-834.10.1016/j.bbrc.2006.12.111256260017194448]Search in Google Scholar
[94. True LD, Zhang H, Ye M, et al. CD90/THY1 is overexpressed in prostate cancer-associated fibroblasts and could serve as a cancer biomarker. Mod Pathol. 2010; 23(10): 1346-1356.10.1038/modpathol.2010.122294863320562849]Search in Google Scholar
[95. Haj-Ahmad TA, Abdalla MA, Haj-Ahmad Y. Potential Urinary Protein Biomarker Candidates for the Accurate Detection of Prostate Cancer among Benign Prostatic Hyperplasia Patients. J Cancer. 2014; 5(2): 103-114.10.7150/jca.6890390976524494028]Search in Google Scholar
[96. Kiprijanovska S, Stavridis S, Stankov O, et al. Mapping and Identification of the Urine Proteome of Prostate Cancer Patients by 2D PAGE/MS. Int J Proteomics. 2014; 2014: 594761.10.1155/2014/594761415814625215235]Search in Google Scholar
[97. Davalieva K, Kiprijanovska S, Komina S, Petrusevska G, Zografska NC, Polenakovic M. Proteomics analysis of urine reveals acute phase response proteins as candidate diagnostic biomarkers for prostate cancer. Proteome Sci. 2015; 13(1): 2.10.1186/s12953-014-0059-9431665025653573]Search in Google Scholar
[98. Jayapalan JJ, Ng KL, Shuib AS, Razack AH, Hashim OH. Urine of patients with early prostate cancer contains lower levels of light chain fragments of interalpha- trypsin inhibitor and saposin B but increased expression of an inter-alpha-trypsin inhibitor heavy chain 4 fragment. Electrophoresis. 2013; 34(11): 1663-1669.10.1002/elps.20120058323417432]Search in Google Scholar
[99. Rehman I, Azzouzi AR, Catto JW, et al. Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot study. Urology. 2004; 64(6): 1238-1243.10.1016/j.urology.2004.06.06315596215]Search in Google Scholar
[100. Okamoto A, Yamamoto H, Imai A, et al. Protein profiling of post-prostatic massage urine specimens by surface-enhanced laser desorption/ionization timeof- flight mass spectrometry to discriminate between prostate cancer and benign lesions. Oncol Rep. 2009; 21(1): 73-79.]Search in Google Scholar
[101. Nakayama K, Inoue T, Sekiya S, et al. The C-terminal fragment of prostate-specific antigen, a 2331 Da peptide, as a new urinary pathognomonic biomarker candidate for diagnosing prostate cancer. PloS one. 2014; 9(9): e107234.10.1371/journal.pone.0107234416939225233230]Search in Google Scholar
[102. Flatley B, Wilmott KG, Malone P, Cramer R. MALDI MS profiling of post-DRE urine samples highlights the potential of beta-microseminoprotein as a marker for prostatic diseases. Prostate. 2014; 74(1): 103-111.10.1002/pros.2273624115268]Search in Google Scholar
[103. Bijnsdorp IV, Geldof AA, Lavaei M, Piersma SR, van Moorselaar RJ, Jimenez CR. Exosomal ITGA3 interferes with non-cancerous prostate cell functions and is increased in urine exosomes of metastatic prostate cancer patients. J Extracell Vesicles. 2013; 2.10.3402/jev.v2i0.22097387312024371517]Search in Google Scholar
[104. Hassan MI, Kumar V, Kashav T, Alam N, Singh TP, Yadav S. Proteomic approach for purification of seminal plasma proteins involved in tumor proliferation. J Sep Sci. 2007; 30(12): 1979-1988.10.1002/jssc.20070002817638362]Search in Google Scholar
[105. Neuhaus J, Schiffer E, von Wilcke P, et al. Seminal plasma as a source of prostate cancer peptide biomarker candidates for detection of indolent and advanced disease. PloS one. 2013; 8(6): e67514.10.1371/journal.pone.0067514369120523826311]Search in Google Scholar
[106. Hanash SM, Pitteri SJ, Faca VM. Mining the plasma proteome for cancer biomarkers. Nature. 2008; 452(7187): 571-579.10.1038/nature0691618385731]Search in Google Scholar
[107. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics. 2002; 1(11): 845-867. 10.1074/mcp.R200007-MCP200]Search in Google Scholar